Arovella Therapeutics Ltd (FRA:E4NA)
€ 0.106 0.001 (0.95%) Market Cap: 124.02 Mil Enterprise Value: 121.87 Mil PE Ratio: 0 PB Ratio: 17.27 GF Score: 28/100

Arovella Therapeutics Ltd at TechKnow Investor Conference - Melbourne Transcript

Aug 03, 2023 / 02:00AM GMT
Release Date Price: €0.023 (+2.22%)
Michael Baker
Arovella Therapeutics Limited - CEO & MD

Great. Thanks very much, Christy, and thanks very much to the organizers for putting the events, of course, big thank you to everybody for taking the time to listen in today, we're delighted to have you here. And so yes, that's exactly what we're talking about Arovella Therapeutics. For those of you that don't know. I said ticker is ALI. and we are a biotechnology company focused on the battle against cancer. I will be making forward-looking statements, so please do take note of the disclaimers.

Now I'd like to start with the highlights of the Company and what we're working on. We determine the invariant natural killer T cell platform, which is a mouthful, and I'll unpack what that means in a moment. And for short, we call it iNKT cells, and we're using that to develop initially treatments for blood cancers.

But as Christy just mentioned, also looking to tactical a range of solid tumors as we build out from behind. So our lead product is ALA-101 that's going after very specific form of blood cancer leukemia or lymphoma. That

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot